• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用历史对照比较生存曲线的研究的样本量考量

Sample size considerations for studies comparing survival curves using historical controls.

作者信息

Dixon D O, Simon R

机构信息

National Cancer Institute, Bethesda, MD 20892.

出版信息

J Clin Epidemiol. 1988;41(12):1209-13. doi: 10.1016/0895-4356(88)90025-x.

DOI:10.1016/0895-4356(88)90025-x
PMID:3062140
Abstract

Formulas are derived for determination of the number of patients needed in a prospective comparison of survival curves, when the control group patients have already been followed for some period. Although an explicit formula for the required sample size is not available, the computing is straightforward, and tables of examples are presented. Situations are described when one might need to allocate some new patients to the control group, rather than exclusively to the experimental group.

摘要

当对照组患者已经随访了一段时间后,推导了用于确定前瞻性比较生存曲线所需患者数量的公式。虽然没有明确的所需样本量公式,但计算很简单,并给出了示例表。描述了在哪些情况下可能需要将一些新患者分配到对照组,而不是仅分配到实验组。

相似文献

1
Sample size considerations for studies comparing survival curves using historical controls.使用历史对照比较生存曲线的研究的样本量考量
J Clin Epidemiol. 1988;41(12):1209-13. doi: 10.1016/0895-4356(88)90025-x.
2
Planning the size of survival time clinical trials with allowance for stratification.考虑分层因素来规划生存时间临床试验的规模。
Stat Med. 1988 May;7(5):559-69. doi: 10.1002/sim.4780070503.
3
Designing for nonparametric Bayesian survival analysis using historical controls.
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):503-6.
4
Sample size: when is enough enough?
Am J Med Sci. 1988 Nov;296(5):360-3. doi: 10.1097/00000441-198811000-00011.
5
Introduction to sample size determination and power analysis for clinical trials.临床试验样本量确定与效能分析简介。
Control Clin Trials. 1981 Jun;2(2):93-113. doi: 10.1016/0197-2456(81)90001-5.
6
Sample size considerations for historical control studies with survival outcomes.具有生存结局的历史对照研究的样本量考量
J Biopharm Stat. 2016;26(4):657-71. doi: 10.1080/10543406.2015.1052495. Epub 2015 Jun 22.
7
Randomised controlled trials: sampling.随机对照试验:抽样
Br J Clin Pharmacol. 1982 May;13(5):631-6. doi: 10.1111/j.1365-2125.1982.tb01429.x.
8
The effect of experimental design parameters on the determination of sample size.实验设计参数对样本量确定的影响。
J Periodontal Res. 1992 Jul;27(4 Pt 2):320-2. doi: 10.1111/j.1600-0765.1992.tb01686.x.
9
Confidence estimation and the size of a clinical trial.置信度估计与临床试验规模
Control Clin Trials. 1984 Jun;5(2):157-63. doi: 10.1016/0197-2456(84)90121-1.
10
Sample size for randomized trials in stroke prevention. How many patients do we need?中风预防随机试验的样本量。我们需要多少患者?
Stroke. 1984 Nov-Dec;15(6):968-71. doi: 10.1161/01.str.15.6.968.

引用本文的文献

1
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.利用神经肿瘤学试验设计和分析中的外部对照数据:要点和风险。
Neuro Oncol. 2024 May 3;26(5):796-810. doi: 10.1093/neuonc/noae005.
2
A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer.一项吉西他滨与厄洛替尼联合治疗后序贯化疗质子治疗加卡培他滨和奥沙利铂用于局部晚期胰腺癌的II期试验。
J Gastrointest Oncol. 2022 Aug;13(4):1989-1996. doi: 10.21037/jgo-22-327.
3
Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.
罕见肿瘤精准肿瘤学的试验设计挑战与方法:儿童肿瘤研究组的经验
JCO Precis Oncol. 2019 Oct 24;3. doi: 10.1200/PO.19.00060. eCollection 2019.
4
Group sequential design for historical control trials using error spending functions.基于误差消耗函数的历史对照试验的分组序贯设计。
J Biopharm Stat. 2020 Mar;30(2):351-363. doi: 10.1080/10543406.2019.1684305. Epub 2019 Nov 12.
5
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.一项评估在标准骨肉瘤治疗中添加贝伐单抗可行性的II期试验。
Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3.
6
Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma.术后淋巴结阳性食管鳞癌调强放疗同步化疗的 II 期临床试验。
Oncol Res. 2017 Sep 21;25(8):1357-1362. doi: 10.3727/096504017X14889842609577. Epub 2017 Mar 8.
7
Survival trial design and monitoring using historical controls.使用历史对照的生存试验设计与监测
Pharm Stat. 2016 Sep;15(5):405-11. doi: 10.1002/pst.1756. Epub 2016 Jun 15.
8
Sample size considerations for historical control studies with survival outcomes.具有生存结局的历史对照研究的样本量考量
J Biopharm Stat. 2016;26(4):657-71. doi: 10.1080/10543406.2015.1052495. Epub 2015 Jun 22.
9
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.头颈部高危鳞状细胞癌的术后放化疗及西妥昔单抗治疗:放射肿瘤学组RTOG-0234
J Clin Oncol. 2014 Aug 10;32(23):2486-95. doi: 10.1200/JCO.2013.53.9163. Epub 2014 Jul 7.
10
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).一项关于常规放疗和沙利度胺治疗幕上初诊胶质母细胞瘤(RTOG 9806)的 II 期研究。
J Neurooncol. 2013 Jan;111(1):33-9. doi: 10.1007/s11060-012-0987-0. Epub 2012 Oct 20.